Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear. METHODS: We randomly assigned 16,492 patients with type 2 diabetes who had a history of, or were at risk for, cardiovascular events to receive saxagliptin or placebo and followed them for a median of 2.1 years. Physicians were permitted to adjust other medications, including antihyperglycemic agents. The primary end point was a composite of cardiovascular death, myocardial infarction, or ischemic stroke. RESULTS: A primary end-point event occurred in 613 patients in the saxagliptin group and in 609 patients in the placebo group (7.3% and 7.2%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio with saxagliptin, 1.00; 95% confidence interval [CI], 0.89 to 1.12; P=0.99 for superiority; P<0.001 for noninferiority); the results were similar in the "on-treatment" analysis (hazard ratio, 1.03; 95% CI, 0.91 to 1.17). The major secondary end point of a composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, coronary revascularization, or heart failure occurred in 1059 patients in the saxagliptin group and in 1034 patients in the placebo group (12.8% and 12.4%, respectively, according to 2-year Kaplan-Meier estimates; hazard ratio, 1.02; 95% CI, 0.94 to 1.11; P=0.66). More patients in the saxagliptin group than in the placebo group were hospitalized for heart failure (3.5% vs. 2.8%; hazard ratio, 1.27; 95% CI, 1.07 to 1.51; P=0.007). Rates of adjudicated cases of acute and chronic pancreatitis were similar in the two groups (acute pancreatitis, 0.3% in the saxagliptin group and 0.2% in the placebo group; chronic pancreatitis, <0.1% and 0.1% in the two groups, respectively). CONCLUSIONS: DPP-4 inhibition with saxagliptin did not increase or decrease the rate of ischemic events, though the rate of hospitalization for heart failure was increased. Although saxagliptin improves glycemic control, other approaches are necessary to reduce cardiovascular risk in patients with diabetes. (Funded by AstraZeneca and Bristol-Myers Squibb; SAVOR-TIMI 53 ClinicalTrials.gov number, NCT01107886.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Trials of HF outcomes with dapagliflozin and empagliflozin, enrolling up to 50% of participants with type 2 diabetes, report reduction in cardiovascular death and improvement of HF among patients with HF with reduced ejection fraction and HF with preserved ejection fraction, respectively, independent of diabetes status, compared with placebo.66–69,88”
From Diagnosis and Treatment of Type 2 Diabetes in Adults: A Review (2025) · cites this paper as [69]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In 4 trials to date, the DPP4 inhibitors have been shown to be neutral in terms of cardiovascular outcomes.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [186]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of SAVOR-TIMI 53 (NCT01107886) and EXAMINE (NCT00968708) were recently released and showed no increased risk of cardiovascular events with the DPP-4 inhibitors saxagliptin96 and alogliptin97, respectively.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [96]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Not all DPP4 inhibitors are associated with higher rates of HF (Table 8).16 -24,184-186”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [19]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Heart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Self-citationThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Cited by
Items 501–600 of 1,020
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Ou, H., Chang, K., Li, C., & Wu, J. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0350-4 · Cited by 73
Kongwatcharapong, J., Dilokthornsakul, P., Nathisuwan, S., Phrommintikul, A., & Chaiyakunapruk, N. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.146 · Cited by 72
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
SGLT2 inhibitors: are they safe?
Filippas-Ntekouan, S., Filippatos, T. D., & Elisaf, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1394152 · Cited by 80
Svanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 71
Giorda, C. B., Sacerdote, C., Nada, E., Marafetti, L., Baldi, I., & Gnavi, R. (2014) · Endocrine · doi:10.1007/s12020-014-0386-8 · Cited by 75
Mosenzon, O., Prato, S. D., Schechter, M., Leiter, L. A., Ceriello, A., DeFronzo, R. A., & Raz, I. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01281-y · Cited by 76
Self-citationVijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 81
A Rock and a Hard Place: Chiseling Away at the Multiple Mechanisms of Aortic Stenosis
Aikawa, E., & Libby, P. (2017) · Circulation · doi:10.1161/circulationaha.117.027776 · Cited by 68
“indicate the need to evaluate DPP-4 inhibitors in this regard, and examine whether they have adverse effects on bone metabolism or promote heart failure, the latter of particular concern in the CAVD population.(15) The recent advances in the mechanistic understanding of CAVD such as the provocative results with DPP-4…”
BackgroundEffects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 78
Dipeptidyl‐peptidase‐4 inhibitors and pancreatic cancer: a cohort study
Gokhale, M., Buse, J. B., Gray, C. L., Pate, V., Marquis, M. A., & Stürmer, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12379 · Cited by 72
“of DPP-4 inhibitors were reported [12,13].”
Zhao, M. H., Chen, J., Yuan, Y., Zou, Z., Lai, X., Rahmani, D. M., Wang, F., Yang, X., Huang, Q., & Bu, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-07921-2 · Cited by 77
Birnbaum, Y., Tran, D., Bajaj, M., & Ye, Y. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0743-0 · Cited by 72
Design of Major Randomized Trials
Pocock, S., Clayton, T. C., & Stone, G. W. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.036 · Cited by 76
Savarese, G., D’Amore, C., Federici, M., Martino, F. D., Dellegrottaglie, S., Marciano, C., Ferrazzano, F., Losco, T., Lund, L. H., Trimarco, B., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.208 · Cited by 76
Nagahisa, T., & Saisho, Y. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00680-5 · Cited by 71
The French Pharmacovigilance Centers Network, Faillie, J.-L., Babai, S., Crépin, S., Bres, V., Laroche, M.-L., Le Louet, H., Petit, P., Montastruc, J.-L., & Hillaire-Buys, D. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0544-0 · Cited by 70
“Recently, two large randomized controlled trials did not find any increased pancreatitis risk with saxagliptin and alogliptin [34, 35].”
Patoulias, D. I., Boulmpou, A., Teperikidis, E., Katsimardou, A., Siskos, F., Doumas, M., Papadopoulos, C. E., & Vassilikos, V. (2021) · World Journal of Cardiology · doi:10.4330/wjc.v13.i10.585 · Cited by 70
Glucagon-like peptide 1 receptor agonists and the risk of incident diabetic retinopathy
Douros, A., Filion, K. B., Yin, H., Yu, O. H., Etminan, M., Udell, J. A., & Azoulay, L. (2018) · Diabetes Care · doi:10.2337/dc17-2280 · Cited by 70
Self-citationGlucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Prattichizzo, F., Sala, L. L., Rydén, L., Marx, N., Ferrini, M., Valensi, P. E., & Ceriello, A. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880040 · Cited by 75
“In detail, analysis of secondary endpoints revealed an increased risk (or a trend towards) for HF for selected DPP-4is, namely saxagliptin and alogliptin.(7,8) A later meta-analysis did, however, question these results.”
ResultWu, H., Xu, L., Zhao, X., Zhang, H., Cheng, K., Wang, X., Chen, M., Li, G., Huang, J., Lan, J., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.062762 · Cited by 71
Anagliptin in the treatment of type 2 diabetes: safety, efficacy, and patient acceptability
Ito, H., Nishio, S., & Abe, M. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s54679 · Cited by 76
Robinson, E., Cassidy, R. S., Tate, M., Zhao, Y., Lockhart, S., Calderwood, D., Church, R., McGahon, M. K., Brazil, D. P., McDermott, B. J., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0476-7 · Cited by 67
“In this regard, it should be noted that the first large-scale GLP-1 cardiovascular trials recently reported that the DPP-4 inhibitors, saxagliptin and alogliptin, did not confer cardiovascular benefit in type 2 diabetes [61, 62], although there are currently no data from long-term randomised clinical trials with GLP-1…”
BackgroundEsposito, K., Chiodini, P., Maiorino, M. I., Bellastella, G., Capuano, A., & Giugliano, D. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005442 · Cited by 68
Liu, J., Li, L., Deng, K., Xu, C., Busse, J. W., Vandvik, P. O., Li, S., Guyatt, G. H., & Sun, X. (2017) · BMJ · doi:10.1136/bmj.j2499 · Cited by 70
Pasternak, B., Wintzell, V., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 69
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 79
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 76
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
Mosenzon, O., Wei, C., Davidson, J., Scirica, B. M., Yanuv, I., Rozenberg, A., Hirshberg, B., Cahn, A., Stahre, C., Strojek, K., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1068 · Cited by 67
Self-citationvon Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F., & Rossing, P. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.04.004 · Cited by 72
DPP-4 inhibitors: pharmacological differences and their clinical implications
Ceriello, A., Sportiello, L., Rafaniello, C., & Rossi, F. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.944862 · Cited by 76
Coronary Artery Disease and Diabetes Mellitus
Aronson, D., & Edelman, E. R. (2015) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.010 · Cited by 74
Lei, Y., Yang, G., Hu, L., Piao, L., Inoue, A., Jiang, H., Sasaki, T., Zhao, G., Yisireyili, M., Yu, C., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.062 · Cited by 70
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., et al. (2016) · Diabetes · doi:10.2337/db15-0122 · Cited by 65
Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
Driessen, J. H. M., van Onzenoort, H. A. W., Henry, R. M. A., Lalmohamed, A., van den Bergh, J. P., Neef, C., Leufkens, H. G. M., & de Vries, F. (2014) · Bone · doi:10.1016/j.bone.2014.07.030 · Cited by 70
“That study showed that there was no significant difference in the number of bone fractures between saxagliptin and placebo users [19].”
BackgroundResultStandl, E., Schnell, O., McGuire, D. K., Ceriello, A., & Rydén, L. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30033-5 · Cited by 73
Self-citationRenal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Williams, D. M., Nawaz, A., & Evans, M. (2020) · Diabetes Therapy · doi:10.1007/s13300-019-00747-3 · Cited by 64
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 71
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
Florentin, M., Kostapanos, M. S., & Papazafiropoulou, A. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i2.85 · Cited by 76
Heppner, K. M., & Tong, J. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0183 · Cited by 71
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
Irons, B. K., & Minze, M. G. (2014) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s38753 · Cited by 78
“They do not appear to have any beneficial cardiovascular effects.(31) Although very well tolerated in clinical trials, there is some fear that these agents are associated with an increased risk of pancreatitis.”
BackgroundOyama, J., Murohara, T., Kitakaze, M., Ishizu, T., Sato, Y., Kitagawa, K., Kamiya, H., Ajioka, M., Ishihara, M., Dai, K., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002051 · Cited by 73
“The SAVOR-TIMI 53 trial reported a significant 27% increase in the incidence of hospitalization for heart failure [16], indicating that it is unclear whether DPP-4 inhibitors have a cardioprotective effect in the clinical setting.”
BackgroundGlucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170174 · Cited by 67
Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes
Faillie, J., Yin, H., Yu, O. H. Y., Herrero, A., Altwegg, R., Renoux, C., & Azoulay, L. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2430 · Cited by 67
Pujadas, G., Nigris, V. D., Prattichizzo, F., Sala, L. L., Testa, R., & Ceriello, A. (2016) · Endocrine · doi:10.1007/s12020-016-1052-0 · Cited by 71
Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy
Phang, R. J., Ritchie, R. H., Hausenloy, D. J., Lees, J. G., & Lim, S. Y. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac049 · Cited by 72
“athy, failed to yield positive outcomes in clinical trials despite promising results shown in preclinical animal models.(5,304,305)”
ResultVaras‐Lorenzo, C., Margulis, A. V., Pladevall, M., Riera‐Guàrdia, N., Calingaert, B., Hazell, L., Romio, S., & Perez‐Gutthann, S. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-129 · Cited by 73
Rosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
“Safety studies, which have been of relatively short duration, have failed to demonstrate special ASCVD benefits by DPP-4 inhibitors [60–62].”
BackgroundFu, J., Zhu, J., Hao, Y.-H., Guo, C., & Zhou, Z. (2016) · Scientific Reports · doi:10.1038/srep29104 · Cited by 67
Xie, X. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.066 · Cited by 72
“Diabetes is considered as a main risky factor, causing various diseases, such as cardiovascular disease [1,2].”
BackgroundSemaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Raz, I., Bhatt, D. L., Hirshberg, B., Mosenzon, O., Scirica, B. M., Umez-Eronini, A., Im, K., Stahre, C., Buskila, A., Iqbal, N., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2546 · Cited by 66
Self-citationDevin, J. K., Pretorius, M., Nian, H., Yu, C., Billings, F. T., & Brown, N. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02767 · Cited by 67
Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes
Ott, C., Raff, U., Schmidt, S., Kistner, I., Friedrich, S., Bramlage, P., Harazny, J. M., & Schmieder, R. E. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-19 · Cited by 74
“001), indicating an improvement of microvascular damage [43].”
BackgroundThe effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
Schernthaner, G., Mogensen, C. E., & Schernthaner, G.-H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114542802 · Cited by 70
Roussel, R., Steg, P. G., Mohammedi, K., Marre, M., & Potier, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13033 · Cited by 66
Self-citationAbrahami, D., Douros, A., Yin, H., Yu, O. H., Faillie, J.-L., Montastruc, F., Platt, R. W., Bouganim, N., & Azoulay, L. (2018) · BMJ · doi:10.1136/bmj.k4880 · Cited by 63
Weng, W., Tian, Y., Kong, S. X., Ganguly, R., Hersloev, M., Brett, J., & Hobbs, T. (2019) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.76 · Cited by 65
Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy
Hasan, A. A., & Hocher, B. (2017) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0005 · Cited by 69
Novel Therapies for Acute Kidney Injury
Chen, H., & Busse, L. W. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.06.020 · Cited by 75
“In addition, the large Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)– Thrombolysis in Myocardial Infarction (TIMI) 53 trial, which evaluated the effect of saxagliptin versus placebo on cardiovascular events in patients with type 2 diabetes mellitus, found that DPP-4 in…”
MethodMolecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
Wanner, C., & Marx, N. (2018) · Diabetologia · doi:10.1007/s00125-018-4678-z · Cited by 65
The Role of Deprescribing in Older Adults with Chronic Kidney Disease
Triantafylidis, L. K., Hawley, C. E., Perry, L., & Paik, J. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0593-8 · Cited by 70
Mamza, J., Marlin, C., Wang, C., Chokkalingam, K., & IDRIS, I. R. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.04.029 · Cited by 67
“[56] was conducted across 16,492 T2DM patients for a median of 2.”
MethodCardiovascular Safety and Sclerostin Inhibition
Langdahl, B. L., Hofbauer, L. C., & Forfar, J. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab193 · Cited by 67
Buzzetti, R., Pozzilli, P., Frederich, R., Iqbal, N., & Hirshberg, B. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2717 · Cited by 62
“[32] and that increases in total daily insulin dose over time were lower with saxagliptin compared with placebo in patients requiring insulin therapy [22].”
BackgroundSelf-citationSchernthaner, G., Durán‐Garcia, S., Hanefeld, M., Langslet, G., Niskanen, L., Östgren, C. J., Malvolti, E., & Hardy, E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12461 · Cited by 64
“The overall cardiovascular safety with saxagliptin was previously assessed in the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) study of ∼16 500 patients with T2D with a history of, or at risk of, cardiovascular events [30].”
BackgroundSystematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes
Bekiari, E., Rizava, C., Athanasiadou, E. A., Papatheodorou, K., Liakos, A., Karagiannis, T., Mainou, M., Rika, M., Boura, P., & Τσάπας, Α. (2015) · Endocrine · doi:10.1007/s12020-015-0841-1 · Cited by 71
Cowan, E., Burch, K. J., Green, B. D., & Grieve, D. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13502 · Cited by 65
“Whilst the precise effects of both endogenous and exogenous obestatin in this setting remain to be determined, the attraction of a dual-action therapeutic targeting both the metabolic and cardiovascular complications of diabetes is clear, particularly in light of the recent large-scale clinical trial data suggesting t…”
BackgroundAbdul-Ghani, M., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 62
Hemmingsen, B., Sonne, D. P., Metzendorf, M.-I., & Richter, B. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012204.pub2 · Cited by 63
Sitagliptin and the risk of hospitalization for heart failure: A population-based study
Wang, K.-L., Liu, C., Chao, T., Huang, C.-M., Wu, C., Chen, S., Yeh, C., Chen, T., Lin, S., & Chiang, C. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.038 · Cited by 64
Singh, J. S., Fathi, A., Vickneson, K., Mordi, I. R., Mohan, M., Houston, J. G., Pearson, E. R., Struthers, A. D., & Lang, C. C. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0419-0 · Cited by 68
“While SAVOR-TIMI-53 revealed that saxagliptin increased HF hospitalisations [21].”
BackgroundRegier, E. E., Venkat, M. V., & Close, K. L. (2016) · Clinical Diabetes · doi:10.2337/cd16-0005 · Cited by 63
“He has participated in clinical trials funded by AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novo Nordisk, Pfizer, Sanofi, and Servier.”
BackgroundInfluentialRenoprotective Effects of DPP-4 Inhibitors
Kawanami, D., Takashi, Y., Takahashi, H., Motonaga, R., & Tanabe, M. (2021) · Antioxidants · doi:10.3390/antiox10020246 · Cited by 66
“01) [110], whether the saxagliptin-mediated reduction of albuminuria was due to a glucose-lowering or an incretin-dependent mechanism remains unclear.”
BackgroundDipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
Daza-Arnedo, R., Rico-Fontalvo, J.-E., Pájaro-Galvis, N., Leal-Martínez, V., Abuabara-Franco, E., Raad-Sarabia, M., Montejo-Hernández, J. D., Cardona-Blanco, M., Cabrales, J., Uparella-Gulfo, I., et al. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.07.007 · Cited by 68
“Myocardial Infarction 53 trial were at higher risk of the secondary outcome of hospitalization due to heart failure (which was a component of a composite) in an otherwise negative study.(58)”
BackgroundFESC, F. E. O. A. D.-4. I. O. L. V. D. D. I. P. W. T. 2. D. A. D. C. (. S. I., Oe, H., Nakamura, K., Kihara, H., Shimada, K., Fukuda, S., Takagi, T., Miyoshi, T., Hirata, K., Yoshikawa, J., et al. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0242-z · Cited by 63
“Recently, the SAVOR-TIMI 53 trial showed that DPP4i may increase the risk of HF [25], which is of concern.”
MethodHeart Failure and Loss of Metabolic Control
Wang, Z. V., Li, D. ‘., & Hill, J. A. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000054 · Cited by 65
“Recently, however, 2 large clinical trials evaluating saxagliptin and alogliptin, inhibiting DPP4 and increasing GLP-1 levels, failed to uncover beneficial cardiovascular effects in patients with type 2 diabetes.(106,107) At a mechanistic level, GLP-1 is generally considered to enhance insulin sensitivity and therefor…”
BackgroundDPP-4 inhibitors: focus on safety
Tella, S. H., & Rendell, M. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.977863 · Cited by 63
“The two recent large multi-center randomized placebo-controlled trials EXAMINE [104] and SAVORTIMI [106] showed no significant difference between the active and placebo groups in acute or chronic pancreatitis.”
BackgroundWhite, W. B., Kupfer, S., Zannad, F., Mehta, C. R., Wilson, C. A., Lei, L., Bakris, G. L., Nissen, S. E., Cushman, W. C., Heller, S. R., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0303 · Cited by 64
Verma, S., Goldenberg, R. M., Bhatt, D. L., Farkouh, M. E., Quan, A., Teoh, H., Connelly, K. A., Leiter, L. A., & Friedrich, J. O. (2017) · CMAJ Open · doi:10.9778/cmajo.20160058 · Cited by 61
Self-citationBlood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk
Bergmark, B. A., Scirica, B. M., Steg, P. G., Fanola, C. L., Gurmu, Y., Mosenzon, O., Cahn, A., Raz, I., Bhatt, D. L., & SAVOR-TIMI 53 Investigators (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx809 · Cited by 61
Self-citationBadjatiya, A., Merrill, P., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., Hernandez, A. F., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008018 · Cited by 73
Perkovic, V., Toto, R., Cooper, M. E., Mann, J. F. E., Rosenstock, J., McGuire, D. K., Kahn, S. E., Marx, N., Alexander, J. H., Zinman, B., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0279 · Cited by 62
Self-citationSalvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Di Martino, A., Albanese, G., Colantuoni, S., Medicamento, G., et al. (2022) · Biomolecules · doi:10.3390/biom12020176 · Cited by 62
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
“The results of the RCTs SAVOR TIMI 53® (saxagliptin [56]), EXAMINE® (alogliptin [57]), TECOS® (sitagliptin [58]), CARMELINA® (linagliptin [59]) on the effect of DPP-4 inhibitors on cardiovascular and renal endpoints each show cardiovascular safety of the investigated DPP-4 inhibitor in their primary endpoints, which w…”
Zhang, X., & Zhao, Q. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000000782 · Cited by 62
“Moreover, an unexpected increased risk of hospitalization for heart failure was found in patients treated with saxagliptin in the SAVOR-TIMI trial [35], which raised considerable concern about the cardiovascular safety of DPP-4 inhibitors in the diabetic population, especially in patients with cardiovascular diseases.”
BackgroundBethel, M. A., Engel, S. S., Green, J. B., Huang, Z., Josse, R. G., Kaufman, K. D., Standl, E., Suryawanshi, S., Van de Werf, F., McGuire, D. K., et al. (2017) · Diabetes Care · doi:10.2337/dc16-1135 · Cited by 62
Self-citationDipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
Silva Júnior, W. S. D., Godoy-Matos, A. F. D., & Kraemer-Aguiar, L. G. (2015) · BioMed Research International · doi:10.1155/2015/816164 · Cited by 61
Abbas, A. S., Dehbi, H. ‐., & Ray, K. K. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12595 · Cited by 62
“296 Abbas et al. Volume 18 No. 3 March 2016 DIABETES, OBESITY AND METABOLISM research letter Study a/ Cardiovascular death + non fatal myocardial infaction + non fatal stroke b/ Cardiovascular death c/ Non fatal myocardial infarction d/ Non fatal stroke e/ Hospitalization for heart failure f/ Acute pancreatitis g/ Pan…”
MethodSelf-citationWang, T., Wang, F., Gou, Z., Tang, H., Li, C., Shi, L., & Zhai, S. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12386 · Cited by 62
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
Self-citationPancreatic Safety of Sitagliptin in the TECOS Study
Buse, J. B., Bethel, M. A., Green, J. B., Stevens, S. R., Lokhnygina, Y. V., Aschner, P. J., Grado, C. A. R., Tankova, T. I., Wainstein, J., Josse, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2780 · Cited by 64
Mentz, R. J., Bethel, M. A., Gustavson, S., Thompson, V. P., Pagidipati, N. J., Buse, J. B., Chan, J. C., Iqbal, N., Maggioni, A. P., Marso, S. P., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.02.005 · Cited by 64
“In the recent large-scale T2DM outcomes trial with the DPP-4 inhibitor saxagliptin (SAVOR), there were observations of increased hospitalization for HF.14,15 Increased hospitalization for HF has not been observed consistently with other DPP-4 inhibitors indicating the lack of a class effect.”
BackgroundInfluentialExploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
Bae, J. H., Kim, S., Park, E.-G., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.1.80 · Cited by 67
“It also should be noted that in those studies renal outcomes were neither primary nor secondary endpoints [13,14].”
Metadata
- Authors
- Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., Cavender, M. A., Udell, J. A., Desai, N. R., Mosenzon, O., McGuire, D. K., Ray, K. K., Leiter, L. A., & Raz, I.
- Affiliations
- Brigham and Women's Hospital (US)
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Hadassah Medical Center (IL)
- St George's, University of London (GB)
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-03
- Volume
- 369
- Issue
- 14
- Pages
- 1317-1326
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2064130493
- Cited by
- 3,470
- References
- 38
- Citations by year
- 2026: 82 · 2025: 137 · 2024: 129 · 2023: 157 · 2022: 182 · 2021: 233 · 2020: 322 · 2019: 324 · 2018: 365 · 2017: 392 · 2016: 422 · 2015: 337 · 2014: 320 · 2013: 57
- FWCI
- 297.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion)
- Hispana (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Griffith Research Online (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- saxagliptin, type 2 diabetes, DPP-4 inhibitors, cardiovascular safety, cardiovascular outcomes, myocardial infarction, ischemic stroke, cardiovascular mortality, heart failure hospitalization, pancreatitis, non-inferiority, antidiabetic drugs, cardiovascular risk stratification, glycemic control
- MeSH terms
- Adamantane, Aged, Aged, 80 and over, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Dipeptides, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Kaplan-Meier Estimate, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.